(OVID) Ovid Therapeutics - NASDAQ
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 445m USD | Total Return: 593.2% in 12m
Avg Turnover: 3.44M
Qual. Beats: 0
Rev. Trend: 90.8%
Qual. Beats: 0
Warnings
Choppy Below Avwap Earnings
Tailwinds
Rs Leader, Idiosyncratic Leader
Ovid Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapies for central nervous system (CNS) disorders. Its primary clinical pipeline includes OV329, a GABA aminotransferase inhibitor targeting drug-resistant epilepsies, and OV4071, an oral KCC2 activator currently in Phase 1 trials for psychiatric symptoms associated with Parkinson’s disease and schizophrenia.
The company operates within the biotechnology sector, which typically requires high research and development expenditure and long regulatory approval timelines through the FDA. To mitigate financial risk and enhance technical expertise, Ovid utilizes a collaborative business model involving licensing agreements with established pharmaceutical entities such as AstraZeneca and Lundbeck.
Investors may find ValueRay useful for deeper analysis of clinical-stage biotech valuations. The companys strategic focus on rare and treatment-resistant neurological conditions targets high-unmet-need markets where successful drug candidates often receive orphan drug designations.
- Clinical trial data readouts for GABA-AT inhibitor OV329 influence investor sentiment
- Progression of Phase 1 oral KCC2 activator OV4071 impacts long-term valuation
- Milestone payments from AstraZeneca and Lundbeck collaborations provide essential non-dilutive capital
- Cash runway and burn rate determine future equity financing and dilution risk
- Regulatory approval pathways for rare epilepsy treatments dictate market entry timelines
| Net Income: -24.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.19 > 0.02 and ΔFCF/TA 42.15 > 1.0 |
| NWC/Revenue: 2.03k% < 20% (prev 6.68k%; Δ -4.65k% < -1%) |
| CFO/TA -0.19 > 3% & CFO -42.0m > Net Income -24.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 10.17 > 1.5 & < 3 |
| Outstanding Shares: last quarter (73.7m) vs 12m ago 3.79% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 4.64% > 50% (prev 0.67%; Δ 3.96% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.64 (Total Current Assets 160.1m - Total Current Liabilities 15.7m) / Total Assets 225.6m |
| B: -1.50 (Retained Earnings -338.7m / Total Assets 225.6m) |
| C: -0.31 (EBIT TTM -47.7m / Avg Total Assets 153.6m) |
| D: 7.25 (Book Value of Equity 198.3m / Total Liabilities 27.4m) |
| Altman-Z'' = 4.83 = AA |
As of June 12, 2026, the stock is trading at USD 2.21 with a total of 2,883,204 shares traded.
Over the past week, the price has changed by -10.89%,
over one month by -20.79%,
over three months by +6.76% and
over the past year by +593.22%.
Ovid Therapeutics has received a consensus analysts rating of 4.83. Therefore, it is recommended to buy OVID.
- StrongBuy: 5
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 5.5 | 147.5% |
P/E Forward = 1.7918
P/S = 62.5016
P/B = 2.3251
Revenue TTM = 7.12m USD
EBIT TTM = -47.7m USD
EBITDA TTM = -47.6m USD
Long Term Debt = unknown (0.0)
Short Term Debt = 1.46m USD (from shortTermDebt, last quarter)
Debt = 14.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 13.1m
Net Debt = -141.0m USD (calculated: Debt 14.5m - CCE 155.5m)
Enterprise Value = 304.1m USD (445.1m + Debt 14.5m - CCE 155.5m)
Interest Coverage Ratio = unknown (Ebit TTM -47.7m / Interest Expense TTM 0.0)
EV/FCF = -7.25x (Enterprise Value 304.1m / FCF TTM -42.0m)
FCF Yield = -13.79% (FCF TTM -42.0m / Enterprise Value 304.1m)
FCF Margin = -589.1% (FCF TTM -42.0m / Revenue TTM 7.12m)
Net Margin = -339.3% (Net Income TTM -24.2m / Revenue TTM 7.12m)
Gross Margin = unknown ((Revenue TTM 7.12m - Cost of Revenue TTM 195k) / Revenue TTM)
Tobins Q-Ratio = 1.35 (Enterprise Value 304.1m / Total Assets 225.6m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 14.5m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -37.7m (EBIT -47.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.17 (Total Current Assets 160.1m / Total Current Liabilities 15.7m)
Debt / Equity = 0.07 (Debt 14.5m / totalStockholderEquity, last quarter 198.3m)
Debt / EBITDA = 2.96 (negative EBITDA) (Net Debt -141.0m / EBITDA -47.6m)
Debt / FCF = 3.36 (negative FCF - burning cash) (Net Debt -141.0m / FCF TTM -42.0m)
Total Stockholder Equity = 107.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -15.73% (Net Income -24.2m / Total Assets 225.6m)
RoE = -22.51% (Net Income TTM -24.2m / Total Stockholder Equity 107.4m)
RoCE = -44.47% (EBIT -47.7m / Capital Employed (Equity 107.4m + L.T.Debt 0.0))
RoIC = -17.87% (negative operating profit) (NOPAT -37.7m / Invested Capital 211.0m)
WACC = 14.35% (E(445.1m)/V(459.7m) * Re(14.82%) + D(14.5m)/V(459.7m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 14.82% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 71.91 | Cagr: 1.89%
[DCF] Fair Price = unknown (Cash Flow -42.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.05 | # QB: 0
Revenue Correlation: 90.81 | Revenue CAGR: 310.3% | SUE: -0.02 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.10 | Chg30d=N/A | Revisions=-50% | Analysts=7
EPS next Quarter (2026-09-30): EPS=-0.11 | Chg30d=N/A | Revisions=-25% | Analysts=7
EPS current Year (2026-12-31): EPS=-0.44 | Chg30d=N/A | Revisions=-27% | GrowthEPS=-91.3% | GrowthRev=-98.5%
EPS next Year (2027-12-31): EPS=-0.45 | Chg30d=N/A | Revisions=-11% | GrowthEPS=-2.6% | GrowthRev=+55.0%
[Analyst] Revisions Ratio: -50%